Clinical Trial Update: A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating immunoPET imaging with 89Zr-DFO-REGN5054 in adults with solid cancers treated with cemiplimab; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 89Zr-DFO-REGN5054 (REGN5054)
• Libtayo (cemiplimab) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: RECRUITING